This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dion's Friday ETF Winners and Losers

NEW YORK ( TheStreet) -- Welcome to Don Dion's Daily ETF Winners and Losers. Be sure to stop by each day to get a feel of who's winning and who's losing when it comes to ETFs.

Winners

iPath S&P 500 VIX Short Term Futures ETN (VXX) 8.9%

Yesterday's "flash crash" sent investors pouring into VIX-based exchange traded funds. Although the fund had been in a downward freefall for more than a year, Thursday and Friday's stumbling markets helped VXX recover nearly all of 2010's losses.

iShares Silver Trust (SLV) 3.9%

Despite a volatile Friday session, physically backed ETFs which track metals linked to industry are pocketing gains. Gold ETFs like the iShares Comex Gold Trust (GLD), on the other hand, were nearly unchanged at mid day trading.

Leading these metals higher is silver, which can be tracked using SLV or ETFS Physical Silver Shares (SIVR).

Global X China Financials ETF (CHIX) 3.4%

While the troubles facing Greece are commanding most of the headlines, there is another economic storm raging in China. Although CHIX is scoring gains today, the nation's banks have struggled recently as China's government attempts to rein in its overheating housing market.

China's markets should be volatile heading into the near future. If investors want to try their luck, I would advise them to avoid large-cap ETFs and opt instead for the Claymore/AlphaShares China Small Cap ETF (HAO).

Losers

iShares Nasdaq Biotechnology Index Fund (IBB) -3.5%

The biotech industry is taking a big hit today. Helping to lead IBB and other biotech ETFs lower during Friday's trading were Dendreon (DNDN) and ImmunoGen (IMGN). Just days ago DNDN rallied big on news that its cancer drug had received approval from the Food and Drug Administration.

The performance of DNDN over the past week highlights how volatile biotech stocks tend to be and how a stronger case can be made for owning an ETF in this space.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
HAO $32.34 -4.21%
CHIX $18.55 -5.07%
XBI $230.78 -1.72%
SLV $15.56 -0.06%
VXX $22.29 3.58%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs